Since the 2000s, significant advances in treating RCC have been achieved, which include drugs targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways.5 The gene discussed is VEGFA; the disease is renal cell carcinoma.